Eur J Nucl Med Mol Imaging DOI 10.1007/s00259-014-2742-6
ORIGINAL ARTICLE
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer Rafke Schoffelen & Wietske Woliner-van der Weg & Eric P. Visser & David M. Goldenberg & Robert M. Sharkey & William J. McBride & Chien-Hsing Chang & Edmund A. Rossi & Winette T. A. van der Graaf & Wim J. G. Oyen & Otto C. Boerman
Received: 4 October 2013 / Accepted: 21 February 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies (bsMAb) and a radiolabeled peptide reduces the radiation dose to normal tissues. Here we report the accuracy of an 111In-labeled pretherapy test dose for personalized dosing of 177 Lu-labeled IMP288 following pretargeting with the anti-CEA × anti-hapten bsMAb, TF2, in patients with metastatic colorectal cancer (CRC). Methods In 20 patients bone marrow absorbed doses (BMD) and doses to the kidneys were predicted based on blood samples and scintigrams acquired after 111In-IMP288 injection for individualized dosing of PRIT with 177Lu-IMP288. Different dose schedules were studied, varying the interval between the bsMAb and peptide administration (5 days vs. 1 day), increasing the bsMAb dose (75 mg vs. 150 mg), and lowering the peptide dose (100 μg vs. 25 μg). Results TF2 and 111In/177Lu-IMP288 clearance was highly variable. A strong correlation was observed between peptide R. Schoffelen : W. Woliner-van der Weg : E. P. Visser : W. J. G. Oyen : O. C. Boerman (*) Department of Radiology and Nuclear Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands e-mail: [email protected] D. M. Goldenberg Garden State Cancer Center, Morris Plains, NJ, USA D. M. Goldenberg : R. M. Sharkey : W. J. McBride : C.
ORIGINAL ARTICLE
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer Rafke Schoffelen & Wietske Woliner-van der Weg & Eric P. Visser & David M. Goldenberg & Robert M. Sharkey & William J. McBride & Chien-Hsing Chang & Edmund A. Rossi & Winette T. A. van der Graaf & Wim J. G. Oyen & Otto C. Boerman
Received: 4 October 2013 / Accepted: 21 February 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies (bsMAb) and a radiolabeled peptide reduces the radiation dose to normal tissues. Here we report the accuracy of an 111In-labeled pretherapy test dose for personalized dosing of 177 Lu-labeled IMP288 following pretargeting with the anti-CEA × anti-hapten bsMAb, TF2, in patients with metastatic colorectal cancer (CRC). Methods In 20 patients bone marrow absorbed doses (BMD) and doses to the kidneys were predicted based on blood samples and scintigrams acquired after 111In-IMP288 injection for individualized dosing of PRIT with 177Lu-IMP288. Different dose schedules were studied, varying the interval between the bsMAb and peptide administration (5 days vs. 1 day), increasing the bsMAb dose (75 mg vs. 150 mg), and lowering the peptide dose (100 μg vs. 25 μg). Results TF2 and 111In/177Lu-IMP288 clearance was highly variable. A strong correlation was observed between peptide R. Schoffelen : W. Woliner-van der Weg : E. P. Visser : W. J. G. Oyen : O. C. Boerman (*) Department of Radiology and Nuclear Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands e-mail: [email protected] D. M. Goldenberg Garden State Cancer Center, Morris Plains, NJ, USA D. M. Goldenberg : R. M. Sharkey : W. J. McBride : C.
